BCRX or CYTK or RDHL
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
BCRX’s FA Score shows that 1 FA rating(s) are green whileCYTK’s FA Score has 1 green FA rating(s), and RDHL’s FA Score reflects 0 green FA rating(s).
- BCRX’s FA Score: 1 green, 4 red.
- CYTK’s FA Score: 1 green, 4 red.
- RDHL’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
BCRX’s TA Score shows that 6 TA indicator(s) are bullish while CYTK’s TA Score has 5 bullish TA indicator(s), and RDHL’s TA Score reflects 4 bullish TA indicator(s).
- BCRX’s TA Score: 6 bullish, 3 bearish.
- CYTK’s TA Score: 5 bullish, 4 bearish.
- RDHL’s TA Score: 4 bullish, 3 bearish.
Price Growth
BCRX (@Biotechnology) experienced а +11.08% price change this week, while CYTK (@Biotechnology) price change was +2.15% , and RDHL (@Pharmaceuticals: Other) price fluctuated +2.65% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +7.20%. For the same industry, the average monthly price growth was -4.19%, and the average quarterly price growth was -12.04%.
The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was +4.63%. For the same industry, the average monthly price growth was -1.43%, and the average quarterly price growth was -9.80%.
Reported Earning Dates
BCRX is expected to report earnings on Jul 31, 2025.
CYTK is expected to report earnings on Jul 31, 2025.
RDHL is expected to report earnings on May 13, 2025.
Industries' Descriptions
@Biotechnology (+7.20% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
@Pharmaceuticals: Other (+4.63% weekly)Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.
| BCRX | CYTK | RDHL | |
| Capitalization | 1.72B | 4.81B | 15.7M |
| EBITDA | 12.8M | -493.48M | 52.8M |
| Gain YTD | 9.309 | -14.264 | -62.641 |
| P/E Ratio | N/A | N/A | N/A |
| Revenue | 451M | 18.5M | 35.7M |
| Total Cash | 321M | 1.08B | 7.01M |
| Total Debt | 809M | 789M | 2.28M |
BCRX | CYTK | RDHL | ||
|---|---|---|---|---|
OUTLOOK RATING 1..100 | 24 | 17 | 1 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 31 Undervalued | 100 Overvalued | 89 Overvalued | |
PROFIT vs RISK RATING 1..100 | 65 | 66 | 100 | |
SMR RATING 1..100 | 100 | 99 | 100 | |
PRICE GROWTH RATING 1..100 | 42 | 85 | 96 | |
P/E GROWTH RATING 1..100 | 100 | 1 | 75 | |
SEASONALITY SCORE 1..100 | n/a | 50 | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
BCRX's Valuation (31) in the Biotechnology industry is somewhat better than the same rating for RDHL (89) and is significantly better than the same rating for CYTK (100). This means that BCRX's stock grew somewhat faster than RDHL’s and significantly faster than CYTK’s over the last 12 months.
BCRX's Profit vs Risk Rating (65) in the Biotechnology industry is in the same range as CYTK (66) and is somewhat better than the same rating for RDHL (100). This means that BCRX's stock grew similarly to CYTK’s and somewhat faster than RDHL’s over the last 12 months.
CYTK's SMR Rating (99) in the Biotechnology industry is in the same range as BCRX (100) and is in the same range as RDHL (100). This means that CYTK's stock grew similarly to BCRX’s and similarly to RDHL’s over the last 12 months.
BCRX's Price Growth Rating (42) in the Biotechnology industry is somewhat better than the same rating for CYTK (85) and is somewhat better than the same rating for RDHL (96). This means that BCRX's stock grew somewhat faster than CYTK’s and somewhat faster than RDHL’s over the last 12 months.
CYTK's P/E Growth Rating (1) in the Biotechnology industry is significantly better than the same rating for RDHL (75) and is significantly better than the same rating for BCRX (100). This means that CYTK's stock grew significantly faster than RDHL’s and significantly faster than BCRX’s over the last 12 months.
| BCRX | CYTK | RDHL | |
|---|---|---|---|
| RSI ODDS (%) | 2 days ago 82% | 2 days ago 71% | 2 days ago 82% |
| Stochastic ODDS (%) | 2 days ago 83% | 2 days ago 90% | 2 days ago 77% |
| Momentum ODDS (%) | 2 days ago 84% | 2 days ago 81% | 2 days ago 90% |
| MACD ODDS (%) | 2 days ago 80% | 2 days ago 69% | N/A |
| TrendWeek ODDS (%) | 2 days ago 79% | 2 days ago 76% | 2 days ago 78% |
| TrendMonth ODDS (%) | 2 days ago 82% | 2 days ago 77% | 2 days ago 89% |
| Advances ODDS (%) | 2 days ago 79% | 2 days ago 78% | 16 days ago 80% |
| Declines ODDS (%) | 18 days ago 80% | 4 days ago 77% | 10 days ago 90% |
| BollingerBands ODDS (%) | 2 days ago 83% | 2 days ago 82% | 2 days ago 81% |
| Aroon ODDS (%) | 2 days ago 82% | 2 days ago 76% | 2 days ago 90% |
BCRX and
Correlation & Price change
A.I.dvisor indicates that over the last year, BCRX has been loosely correlated with VCYT. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if BCRX jumps, then VCYT could also see price increases.
| Ticker / NAME | Correlation To BCRX | 1D Price Change % | ||
|---|---|---|---|---|
| BCRX | 100% | +3.27% | ||
| VCYT - BCRX | 46% Loosely correlated | +2.15% | ||
| OCGN - BCRX | 44% Loosely correlated | +2.78% | ||
| ETNB - BCRX | 38% Loosely correlated | +4.23% | ||
| DNLI - BCRX | 38% Loosely correlated | +4.17% | ||
| ARWR - BCRX | 38% Loosely correlated | +2.54% | ||
More | ||||
RDHL and
Correlation & Price change
A.I.dvisor tells us that RDHL and EOLS have been poorly correlated (+29% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that RDHL and EOLS's prices will move in lockstep.
| Ticker / NAME | Correlation To RDHL | 1D Price Change % | ||
|---|---|---|---|---|
| RDHL | 100% | +3.57% | ||
| EOLS - RDHL | 29% Poorly correlated | +2.85% | ||
| ACET - RDHL | 27% Poorly correlated | +2.13% | ||
| PTPI - RDHL | 26% Poorly correlated | +3.43% | ||
| SNOA - RDHL | 23% Poorly correlated | -2.28% | ||
| DVAX - RDHL | 23% Poorly correlated | +1.21% | ||
More | ||||